Etretinate
Tegison (etretinate) is a small molecule pharmaceutical. Etretinate was first approved as Tegison on 1986-09-30. It is used to treat psoriasis in the USA.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| skin and connective tissue diseases | D017437 |
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Etretinate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| TEGISON | Roche | N-019369 DISCN | 1986-09-30 | 2 products |
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| psoriasis | EFO_0000676 | D011565 | L40 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
82 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Contraception | D003267 | 2 | 5 | 4 | 14 | 13 | 38 | ||
| Hiv | D006678 | O98.7 | — | 1 | — | 3 | 2 | 6 | |
| Hiv infections | D015658 | EFO_0000764 | B20 | — | 1 | — | 2 | 2 | 5 |
| Bacterial vaginosis | D016585 | EFO_0003932 | — | — | — | 3 | — | 3 | |
| Breast feeding | D001942 | — | — | — | 1 | 2 | 3 | ||
| Drug interactions | D004347 | — | — | — | 1 | 1 | 2 | ||
| Postcoital contraception | D044363 | — | — | — | 1 | 1 | 2 | ||
| Endometriosis | D004715 | EFO_0001065 | N80 | — | 1 | 1 | 1 | — | 2 |
| Sickle cell anemia | D000755 | EFO_0000697 | D57 | — | — | — | 2 | — | 2 |
| Polycystic ovary syndrome | D011085 | EFO_0000660 | E28.2 | — | — | — | 1 | — | 1 |
Show 3 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Contraception behavior | D003268 | — | — | 1 | — | 2 | 3 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Dysmenorrhea | D004412 | HP_0100607 | N94.6 | — | 2 | — | — | — | 2 |
| Prostatic hyperplasia | D011470 | EFO_0000284 | N40 | — | 1 | — | — | — | 1 |
| Uterine hemorrhage | D014592 | — | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hormonal contraception | D000080282 | — | — | — | — | 2 | 2 | ||
| Pregnancy | D011247 | EFO_0002950 | Z33.1 | — | — | — | — | 2 | 2 |
| Pharmacokinetics | D010599 | — | — | — | — | 1 | 1 | ||
| Opioid-related disorders | D009293 | EFO_0005611 | F11 | — | — | — | — | 1 | 1 |
| Sexual behavior | D012725 | — | — | — | — | 1 | 1 | ||
| Menorrhagia | D008595 | N92.0 | — | — | — | — | 1 | 1 | |
| Weights and measures | D014894 | — | — | — | — | 1 | 1 | ||
| Therapeutic abortion | D000032 | — | — | — | — | 1 | 1 | ||
| Induced abortion | D000028 | — | — | — | — | 1 | 1 | ||
| Infertility | D007246 | EFO_0000545 | — | — | — | — | 1 | 1 |
Show 3 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | ETRETINATE |
| INN | etretinate |
| Description | Etretinate is a retinoid, an enoate ester and an ethyl ester. It has a role as a keratolytic drug. |
| Classification | Small molecule |
| Drug class | retinol derivatives |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CCOC(=O)/C=C(C)/C=C/C=C(C)/C=C/c1c(C)cc(OC)c(C)c1C |
Identifiers
| PDB | — |
| CAS-ID | 54350-48-0 |
| RxCUI | 4182 |
| ChEMBL ID | CHEMBL464 |
| ChEBI ID | 4913 |
| PubChem CID | 5282375 |
| DrugBank | DB00926 |
| UNII ID | 65M2UDR9AG (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,146 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
70,005 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more